Novavax (NVAX) Shares are Down -83.44%

Novavax (NVAX) : During the past 4 weeks, traders have been relatively bearish on Novavax (NVAX), hence the stock is down -81.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -83.53% relative to the S&P 500. The 4-week change in the price of the stock is -81.62% and the stock has fallen -83.44% in the past 1 week.

The stock has recorded a 20-day Moving Average of 82.46% and the 50-Day Moving Average is 82.54%.The 200 Day SMA reached 79.67% Novavax, Inc. has dropped 80.72% during the last 3-month period . Year-to-Date the stock performance stands at -84.62%.


Novavax (NVAX) : The consensus price target for Novavax (NVAX) is $11.98 for the short term with a standard deviation of $3.59. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $14, however, the pessimist price target for the company is $6.

For the current week, the company shares have a recommendation consensus of Buy. Novavax (NASDAQ:NVAX): stock was range-bound between the intraday low of $1.16 and the intraday high of $1.68 after having opened at $1.17 on Fridays session. The stock finally closed in the red at $1.17, a loss of -84.53%. The stock remained in the red for the whole trading day. The total traded volume was 242,232,490 shares. The stock failed to cross $1.68 in Fridays trading. The stocks closing price on Thursday was $1.29.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.